Wall Street analysts expect Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) to announce $0.18 earnings per share for the current fiscal quarter, according to Zacks. Nine analysts have issued estimates for Allscripts Healthcare Solutions’ earnings, with the lowest EPS estimate coming in at $0.17 and the highest estimate coming in at $0.20. Allscripts Healthcare Solutions reported earnings per share of $0.14 during the same quarter last year, which indicates a positive year-over-year growth rate of 28.6%. The company is scheduled to report its next earnings report on Thursday, February 15th.

According to Zacks, analysts expect that Allscripts Healthcare Solutions will report full year earnings of $0.62 per share for the current year, with EPS estimates ranging from $0.60 to $0.64. For the next financial year, analysts expect that the firm will report earnings of $0.75 per share, with EPS estimates ranging from $0.72 to $0.80. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Allscripts Healthcare Solutions.

MDRX has been the topic of several research reports. Zacks Investment Research downgraded Allscripts Healthcare Solutions from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Citigroup initiated coverage on Allscripts Healthcare Solutions in a report on Thursday. They set a “buy” rating on the stock. Cowen upgraded Allscripts Healthcare Solutions from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $13.00 to $16.00 in a report on Monday, September 11th. Royal Bank of Canada initiated coverage on Allscripts Healthcare Solutions in a report on Tuesday, September 19th. They issued an “outperform” rating and a $17.00 price target on the stock. Finally, Maxim Group reiterated a “buy” rating and issued a $16.00 price target on shares of Allscripts Healthcare Solutions in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $14.94.

In other news, President Richard J. Poulton sold 15,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $14.26, for a total value of $213,900.00. Following the completion of the sale, the president now owns 1,351,773 shares of the company’s stock, valued at approximately $19,276,282.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP James Hewitt sold 36,796 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $14.11, for a total value of $519,191.56. Following the completion of the sale, the senior vice president now directly owns 181,766 shares of the company’s stock, valued at approximately $2,564,718.26. The disclosure for this sale can be found here. Insiders sold a total of 56,796 shares of company stock worth $804,842 over the last quarter. Company insiders own 0.75% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Archford Capital Strategies LLC boosted its position in shares of Allscripts Healthcare Solutions by 6,124.0% in the 2nd quarter. Archford Capital Strategies LLC now owns 6,224 shares of the software maker’s stock worth $958,000 after purchasing an additional 6,124 shares in the last quarter. Bank of Montreal Can lifted its position in Allscripts Healthcare Solutions by 6.9% during the 2nd quarter. Bank of Montreal Can now owns 10,603 shares of the software maker’s stock worth $135,000 after acquiring an additional 689 shares during the period. ETF Managers Group LLC acquired a new stake in Allscripts Healthcare Solutions during the 2nd quarter worth about $152,000. Sheaff Brock Investment Advisors LLC acquired a new stake in Allscripts Healthcare Solutions during the 3rd quarter worth about $174,000. Finally, Crossmark Global Holdings Inc. acquired a new stake in Allscripts Healthcare Solutions during the 3rd quarter worth about $187,000.

Allscripts Healthcare Solutions (NASDAQ:MDRX) opened at $15.18 on Friday. The company has a market capitalization of $2,730.09, a price-to-earnings ratio of -13.09, a price-to-earnings-growth ratio of 2.14 and a beta of 1.33. Allscripts Healthcare Solutions has a fifty-two week low of $10.24 and a fifty-two week high of $15.32. The company has a current ratio of 0.98, a quick ratio of 0.98 and a debt-to-equity ratio of 1.20.

WARNING: “Zacks: Analysts Expect Allscripts Healthcare Solutions Inc (MDRX) Will Post Earnings of $0.18 Per Share” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://theolympiareport.com/2018/01/05/zacks-analysts-expect-allscripts-healthcare-solutions-inc-mdrx-will-post-earnings-of-0-18-per-share.html.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Get a free copy of the Zacks research report on Allscripts Healthcare Solutions (MDRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.